RxDoctor Payments Data

Homeyar Dinshaw, MD

Cardiovascular Disease · Metairie, LANPI 1578521605

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $11,696 of the $13,598 with a category attached, or 86.0%. Siemens Medical Solutions USA, Inc. accounts for 73.6% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $10,018 and has fallen 82.1% since, to $1,795 in 2025.

$13,598in general payments, 2019–2025

Across 75 payments — averaging $181.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$10K
  • Edwards Lifesciences$2K
  • Abbott$1K
  • Amgen$205
  • GE HealthCare$138
  • Boston Scientific$131
  • plus $300 from 8 others

What the payments were for

  • Travel & lodging$11,69686%
  • Food & beverage$1,89014%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,598 in reported general payments places this provider in the 85th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$60,871
Medicare patients
881
Services billed
1,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban355$307,925
EntrestoSacubitril/Valsartan178$161,796
XareltoRivaroxaban152$133,544
Repatha SureclickEvolocumab172$112,559
JardianceEmpagliflozin85$67,382
Praluent PenAlirocumab51$39,539
Repatha SyringeEvolocumab30$17,581
VascepaIcosapent Ethyl47$17,237
NexlizetBempedoic Acid/Ezetimibe16$13,905
BrilintaTicagrelor17$10,752
CorlanorIvabradine Hcl16$5,721
Rosuvastatin Calcium500$5,092
Atorvastatin Calcium576$4,526
Metoprolol Succinate444$4,423
Ezetimibe350$4,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$307,925355 claims
NovartisEntresto$92$161,796178 claims
Johnson & JohnsonXarelto$77$133,544152 claims
AmgenCorlanor$205$5,72116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →